Across hundreds of patients I have treated with GLP-1 class medications, true pharmacological tolerance remains extremely rare
The fact that retatrutide addresses multiple cardiovascular risk factors simultaneouslyweight, blood pressure, lipids, and inflammationsuggests it could have profound impacts on long-term health outcomes
If you see GLP-1/GIP, it is tirzepatide
This is nothing to be concerned about
Timing differences between the peptides also contribute to synergy
Thus, exenatide treated patients maintained their cognitive benefit 12-months following drug cessation, however, it should be noted that cognitive scores also remained unchanged for controls between 12 and 24 months